Profile: Achieve Life Sciences Inc (ACHV.OQ)
20 Sep 2019
Achieve Life Sciences, Inc. incorporated on March 22, 1995, is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide.
Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
Custirsen is being evaluated in two Phase III trials; one in patients with prostate cancer and one in patients with non-small cell lung cancer (NSCLC). Custirsen is designed to inhibit the production of clusterin. The Company and collaborating investigators have conducted a Phase III clinical trial and over five Phase II clinical trials to evaluate the ability of Custirsen to enhance the effects of therapy in prostate, non-small cell lung and breast cancers. The SYNERGY Phase III trial was designed to evaluate a survival benefit for Custirsen, in combination with first-line docetaxel chemotherapy, in men with metastatic castrate-resistant prostate cancer (CRPC). The Company's AFFINITY trial is a Phase III clinical trial to evaluate a survival benefit for Custirsen. ENSPIRIT trial is a Phase III clinical trial to evaluate a survival benefit for Custirsen in combination with docetaxel treatment as second-line chemotherapy, in patients with NSCLC.
OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5), two proteins that affect the growth of cancer cells when overexpressed. Preclinical studies with human prostate and breast cancer cells have shown that reducing IGFBP-2 and IGFBP-5 production with OGX-225 sensitized these tumor types to hormone ablation therapy or chemotherapy and induced tumor cell death. The Company has completed Investigational New Drug (IND) enabling toxicology studies for OGX-225.
Achieve Life Sciences Inc
520 Pike St Ste 2250
SEATTLE WA 98101-4013